Lepu Biopharma Secures Upfront Payment and Sets Royalty Terms in Excalipoint Licensing Deal

Lepu Biopharma Co. Ltd. Class H ( (HK:2157) ) has shared an update.

Lepu Biopharma has confirmed that all conditions precedent under its Share Purchase Agreement with Excalipoint have been satisfied and that it has received the first tranche of upfront payment under their Intellectual Property Assignment and License Agreement, marking a key milestone in monetizing its CTM012 and CTM013 oncology pipeline assets. The company also disclosed a tiered royalty framework under which Excalipoint will pay annual royalties on a product-by-product basis once commercial sales commence, including illustrative payments of US$85 million on annual net sales of US$2.5 billion for each licensed product and a 5% royalty on sales beyond that threshold, underscoring the potential for substantial recurring revenue and strengthening Lepu Biopharma’s long-term commercialization and partnership strategy in cancer therapeutics.

The most recent analyst rating on (HK:2157) stock is a Sell with a HK$5.00 price target. To see the full list of analyst forecasts on Lepu Biopharma Co. Ltd. Class H stock, see the HK:2157 Stock Forecast page.

More about Lepu Biopharma Co. Ltd. Class H

Lepu Biopharma Co., Ltd. is a PRC-incorporated biopharmaceutical company listed in Hong Kong that focuses on the research, development and commercialization of oncology therapeutic drug candidates. Through its subsidiaries, including wholly owned unit Innocube, the group develops cancer-focused pipeline products, while its partner Excalipoint Companies specialize in pharmaceutical R&D aimed at bringing targeted products to market.

Average Trading Volume: 11,497,463

Technical Sentiment Signal: Sell

Current Market Cap: HK$9.81B

Find detailed analytics on 2157 stock on TipRanks’ Stock Analysis page.